Milestone Pharmaceuticals Inc.

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 31

By Therapeutic Area

top 1

Cardiovascular

1100%

R&D Momentum

32/100

Pipeline Velocity

6/100

Trial Completion Rate

60/100

Pipeline Concentration

100/100

Pipeline Freshness

78/100

Activity

Key Events

Dec 12, 2025FDACardamyst — CARDAMYST

Dec 11, 2023TrialThe NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

Dec 13, 2021TrialEtripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Nov 19, 2020TrialReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Sep 23, 2019TrialSafety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

Dec 10, 2018TrialSafety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Jun 18, 2018TrialEfficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Cardamyst4 patentsJun 19, 2028 CardamystApr 13, 2036 CardamystJul 15, 2042

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular

Atrial Fibrillation

Cardamyst

Paroxysmal Supraventricular Tachycardia

Cardamyst

Cardiovascular

Atrial Fibrillation

CardamystPhase 3

Paroxysmal Supraventricular Tachycardia

CardamystPhase 3

Regulatory

Regulatory Timeline

19824 events

FDAOct 29

Saline — BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA018800 (NDA)

FDAOct 29

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA018803 (NDA)

FDAFeb 19

Saline — SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

Application NDA018497 (NDA)

FDAJan 1

Saline — SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

Application NDA018090 (NDA)

19831 event

FDANov 1

Saline — SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

Application NDA019022 (NDA)

19842 events

FDAJul 20

Saline — SODIUM CHLORIDE 14.6%

Application NDA018897 (NDA)

FDAJul 13

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA019218 (NDA)

19854 events

FDAOct 30

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA016677 (NDA)

FDASep 17

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA019480 (NDA)

FDAJul 15

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA019465 (NDA)

FDAMay 17

Saline — SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

Application NDA019319 (NDA)

19871 event

FDAApr 22

Saline — SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

Application NDA019329 (NDA)

19882 events

FDAJun 8

Saline — SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

Application NDA019759 (NDA)

FDAMar 9

Saline — SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

Application NDA019635 (NDA)

19922 events

FDADec 7

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA020178 (NDA)

FDASep 3

Saline — BRONCHO SALINE

Application NDA019912 (NDA)

19981 event

FDANov 18

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA019217 (NDA)

20061 event

FDAJul 27

Saline — SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Application NDA021569 (NDA)

20121 event

FDAJan 6

Saline — SODIUM CHLORIDE 0.9%

Application NDA202832 (NDA)

20251 event

FDADec 12

Cardamyst — CARDAMYST

Application NDA218571 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)